# Gastric Sleeve vs GLP-1: Weight Loss, Diabetes, Risks Source: https://www.dietglp.com/blog/gastric-sleeve-vs-glp-1/ Published: 2026-10-30 Keywords: gastric sleeve vs glp 1, gastric bypass vs glp 1, bariatric surgery vs glp 1, is weight loss surgery or glp 1 better, which is better gastric sleeve or glp 1, glp 1 after gastric sleeve, glp 1 medication after gastric sleeve, gastric bypass vs sleeve vs glp 1, sleeve gastrectomy vs glp 1, bariatric surgery vs glp 1 agonist, glp-1 in gastric bypass patients, weight loss surgery or glp 1 **TL;DR:** In studies, a gastric sleeve or bypass usually takes off more weight than a GLP-1 drug, and the effect lasts without a weekly shot. In a large 2025 real-world study, surgery patients lost about 24% of body weight at two years versus 4.7% for people prescribed semaglutide or tirzepatide, mostly because many stopped their medicine. In trials where people stayed on the drug, weight loss was about 15% (Wegovy) to 21% (Zepbound). The best choice depends on your BMI, health, budget and how you feel about surgery, so it is a decision for you and your doctor. Either way, [Sharpy](https://apps.apple.com/us/app/glp-diet-app-sharpy/id6762084138) helps you protect muscle with one protein target and one 20-minute workout a day. Is a gastric sleeve better than a GLP-1 drug like Wegovy or Zepbound? For pure weight loss, studies say surgery usually wins. A sleeve or bypass takes off more weight on average and keeps working without a weekly shot. But GLP-1 drugs skip the operating room, can be stopped, and work well for people who stay on them. A new long-term diabetes study out this week has put the question back in the news, so here is what the numbers actually show. ## Gastric sleeve vs GLP-1 at a glance | | Gastric sleeve | GLP-1 drug (Wegovy, Zepbound) | |---|---|---| | What it is | Surgery that removes most of the stomach | Weekly shot or daily pill that curbs appetite | | Average weight loss | About 24% at 2 years in a 2025 real-world study (sleeve or bypass) | 14.9% (Wegovy, 68 weeks) to 20.9% (Zepbound 15 mg, 72 weeks) in trials with steady use | | Real-world weight loss | Similar to trials | 4.7% at 2 years in the same 2025 study, often because people stopped | | Who qualifies | BMI 35+, or 30 to 34.9 with metabolic disease (ASMBS/IFSO 2022) | BMI 30+, or 27+ with a weight-related condition (FDA label) | | Can you undo it? | No | Yes, but weight often returns after stopping | | Lifelong needs | Vitamin supplements and follow-up | Ongoing prescription to keep the effect | | Main downsides | Surgical risk, reflux, nutrient gaps | Nausea, vomiting, constipation, ongoing cost | ## Bariatric surgery vs GLP-1: the head-to-head study The biggest direct comparison so far came from NYU Langone and NYC Health + Hospitals. Researchers looked at health records for 51,085 adults with a BMI of 35 or more who had a sleeve or bypass, or got a prescription for semaglutide or tirzepatide, between 2018 and 2024. They presented it at the ASMBS meeting in June 2025. - Surgery patients lost about 58 pounds, or 24% of body weight, at two years. - People prescribed a GLP-1 for at least six months lost about 12 pounds, or 4.7%. - People who stayed on the drug for a full year lost about 7%. - NYU's own release used a slightly different count (26.5% vs 5.7%) and said tirzepatide users did best among drug users, at 8.9%. Two cautions. This was not a randomized trial, so the groups were not the same at the start. And many people on GLP-1s stopped or took lower doses, which is common in real life because of cost, coverage and side effects. ## What the GLP-1 trials show when people stay on the drug Clinical trials tell a different story because people kept taking the medicine at full dose. In STEP 1 (NEJM, 2021), semaglutide 2.4 mg led to 14.9% weight loss at 68 weeks versus 2.4% on placebo. In SURMOUNT-1 (NEJM, 2022), tirzepatide 15 mg led to 20.9% at 72 weeks. That is closer to surgery, but only for as long as you keep taking it. See our [GLP-1 medication comparison](/blog/glp1-medication-comparison/) for how the drugs stack up against each other. ## Gastric sleeve vs GLP-1 for type 2 diabetes On October 26, 2026, the University of Oklahoma announced new results from the ARMMS-T2D study in Diabetes Care. It followed 262 adults with type 2 diabetes: 166 had metabolic-bariatric surgery and 96 had medical and lifestyle care. - After a median of 11 years (some up to 14), 58% of the surgery group were in remission, versus 3% of the medical group. - Remission meant an A1C below 6.5% without any blood sugar medicine. - People were more likely to reach remission if they had diabetes for a shorter time, did not use insulin, took fewer diabetes drugs, and lost more weight in the first year. - People with a longer diabetes history were more likely to relapse. The study did not report results for sleeve and bypass separately in the announcement, and the medical group was not a trial of today's GLP-1 drugs. Still, it is the longest look yet at how lasting remission after surgery can be. If you have type 2 diabetes and would rather start with a pill, our [orforglipron for type 2 diabetes guide](/blog/orforglipron-type-2-diabetes/) covers the newest oral option and its FDA status. ## Gastric bypass vs sleeve vs GLP-1 Bypass and sleeve are not the same. The Finnish SLEEVEPASS trial randomized 240 adults to one or the other and followed them for 10 years (JAMA Surgery, 2022). | Outcome at 10 years | Sleeve | Bypass | |---|---|---| | Median excess weight lost | 43.5% | 50.7% | | Reflux damage to the esophagus (esophagitis) | 31% | 7% | | High blood pressure remission | 8% | 24% | | Diabetes, cholesterol, sleep apnea | No clear difference | No clear difference | So bypass took off a little more weight and caused less reflux, while the sleeve is a simpler operation. Both usually beat GLP-1 drugs on weight in real-world data. Your surgeon is the right person to weigh which one fits you. ## Can you take a GLP-1 after a gastric sleeve? Yes. Doctors sometimes add a GLP-1 when weight loss after surgery stalls or weight creeps back. The BARI-OPTIMISE trial (JAMA Surgery, 2023) tested this in 70 people who had lost 20% or less of their weight after surgery. Most had a sleeve. Over 24 weeks, those on liraglutide 3.0 mg lost about 8.8% more of their weight, versus about 0.5% on placebo. That trial used liraglutide, an older daily GLP-1. Whether and which drug makes sense after your surgery is a question for your surgeon and prescriber, not something to start on your own. ## Muscle matters with both Fast weight loss, from a scalpel or a shot, can take muscle with it. That is why protein and strength work matter in both paths. Each meal is smaller after a sleeve and appetite is lower on a GLP-1, so protein has to come first on the plate. [Sharpy](https://apps.apple.com/us/app/glp-diet-app-sharpy/id6762084138) gives you one daily protein target, one 20-minute workout and a Shape Score, so you can see whether you are losing fat and keeping muscle. Our guide to [sarcopenia and GLP-1](/blog/sarcopenia-and-glp1/) explains why this matters more as you age. ## How to decide: questions to bring to your doctor - What is my BMI, and do I qualify for surgery, a GLP-1, or both? - Do I have type 2 diabetes, sleep apnea, reflux or other conditions that change the choice? - Will my insurance cover surgery, the drug, or neither? Our [GLP-1 cost and coverage guide](/blog/glp1-cost-and-coverage/) can help with that part. - Am I ready to take a medicine long term, or would I rather have a one-time procedure with lifelong follow-up? - If I try a GLP-1 first and stop, what is the plan to keep weight off? See [how to stop GLP-1 without rebound](/blog/how-to-stop-glp1-without-rebound/). If you are pregnant, planning a pregnancy, under 18, or have a history of an eating disorder, talk with your doctor before either option. ## The bottom line Surgery gives the most weight loss and the strongest long-term diabetes data, but it is permanent and carries surgical risks. GLP-1 drugs avoid surgery and work well while you take them, though real-world results drop when people stop. Many people now use both, a GLP-1 before or after surgery, with their care team. Whichever path you choose, [Sharpy](https://apps.apple.com/us/app/glp-diet-app-sharpy/id6762084138) helps you keep the muscle that keeps your results. ## Sources - [Weight-loss surgery leads to lasting diabetes remission, long-term study finds, University of Oklahoma, October 26, 2026](https://ou.edu/news/articles/2026/october/weight-loss-surgery-lasting-diabetes-remission-long-term-study) - [Predictors of type 2 diabetes remission and relapse in ARMMS-T2D, Diabetes Care](https://doi.org/10.2337/dc26-1070) - [Head-to-head study shows bariatric surgery superior to GLP-1 drugs for weight loss, ASMBS, June 17, 2025](https://asmbs.org/news_releases/head-to-head-study-shows-bariatric-surgery-superior-to-glp-1-drugs-for-weight-loss/) - [NYU Langone experts present research at 2025 ASMBS meeting](https://nyulangone.org/news/nyu-langone-experts-present-latest-research-weight-loss-surgery-outcomes-techniques-2025-asmbs-annual-meeting) - [SLEEVEPASS 10-year results, JAMA Surgery, 2022](https://pmc.ncbi.nlm.nih.gov/articles/PMC9218929/) - [BARI-OPTIMISE randomized clinical trial, JAMA Surgery, 2023](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372755/) - [ASMBS/IFSO 2022 indications for metabolic and bariatric surgery](https://asmbs.org/wp-content/uploads/2022/10/ASMBS-IFSO-Guidelines-2022-PIIS1550728922006414.pdf) - [Once-weekly semaglutide in adults with overweight or obesity (STEP 1), NEJM, 2021](https://pubmed.ncbi.nlm.nih.gov/33567185/) - [Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1), NEJM, 2022](https://pubmed.ncbi.nlm.nih.gov/35658024/) ## Frequently asked questions **Q: Is weight loss surgery or a GLP-1 better?** A: On average, surgery leads to more weight loss and it does not depend on taking a drug every week. GLP-1 drugs avoid an operation, can be stopped, and work well for people who stay on them. Which is better for you depends on your BMI, other conditions, surgical risk, cost and coverage. Talk it through with your doctor and, if you are a candidate, a bariatric surgery team. **Q: How much weight do you lose with a gastric sleeve vs a GLP-1?** A: In a 2025 NYU Langone study of 51,085 patients with a BMI of 35 or more, sleeve or bypass patients lost about 24% of their body weight at two years. People prescribed semaglutide or tirzepatide lost 4.7%, or about 7% if they stayed on the drug for a full year. In clinical trials with steady use, Wegovy averaged 14.9% at 68 weeks and Zepbound 15 mg averaged 20.9% at 72 weeks. **Q: Can you take a GLP-1 after a gastric sleeve?** A: Yes, some doctors prescribe one when weight loss after surgery is lower than hoped or weight comes back. In the BARI-OPTIMISE trial, people who had lost 20% or less after surgery (most had a sleeve) lost about 8.8% more on liraglutide 3.0 mg over 24 weeks, versus about 0.5% on placebo. This is a decision for your surgeon and prescriber. **Q: Which is better for type 2 diabetes, surgery or a GLP-1?** A: Surgery has the strongest long-term remission data. In the ARMMS-T2D study published in Diabetes Care in October 2026, 58% of people who had metabolic-bariatric surgery reached remission (A1C under 6.5% without diabetes drugs) versus 3% with medical and lifestyle care, over a median of 11 years. GLP-1 drugs lower A1C well but are usually taken long term. **Q: Gastric bypass vs sleeve vs GLP-1: which loses the most?** A: In the 10-year SLEEVEPASS trial, bypass patients lost a bit more excess weight than sleeve patients (median 50.7% vs 43.5% of excess weight). Both usually lose more than people on GLP-1 drugs in real-world studies. Sleeve patients had more reflux-related esophagitis (31% vs 7%). **Q: Who qualifies for a gastric sleeve vs a GLP-1?** A: Under the 2022 ASMBS and IFSO guidelines, surgery is recommended at a BMI of 35 or more and can be considered at 30 to 34.9 with metabolic disease. Wegovy and Zepbound are approved for adults with a BMI of 30 or more, or 27 or more with at least one weight-related condition.